NeoGenomics (NEO) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of NeoGenomics (NASDAQ: NEO) in the last few weeks:

• 2/24/2026 – NeoGenomics had its price target raised by Piper Sandler from $12.00 to $13.00. They now have an “overweight” rating on the stock.
• 2/20/2026 – NeoGenomics was downgraded by Zacks Research from “strong-buy” to “hold”.
• 2/18/2026 – NeoGenomics had its “hold” rating reaffirmed by UBS Group AG.
• 2/18/2026 – NeoGenomics had its “hold” rating reaffirmed by Benchmark Co..
• 2/17/2026 – NeoGenomics had its price target raised by Needham & Company LLC from $14.00 to $15.00. They now have a “buy” rating on the stock.
• 1/12/2026 – NeoGenomics was upgraded by Zacks Research from “hold” to “strong-buy”.
• 1/12/2026 – NeoGenomics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $14.00 price target on the stock.

Insider Transactions at NeoGenomics

In other NeoGenomics news, COO Warren Stone sold 22,128 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total transaction of $276,600.00. Following the transaction, the chief operating officer owned 121,631 shares of the company’s stock, valued at approximately $1,520,387.50. This represents a 15.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.40% of the company’s stock.

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.